ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
N2012-01: NANT 2012-01 Phase 1 study of Difluoromethylornithine (DFMO) and celecoxib with cyclophosphamide/topotecan for patients with relapsed or refractory neuroblastoma
Protocol ID
N2012-01
Condition/s
Neuroblastoma
Diagnosis Stage
Relapse/ refractory
Sponsor
New Approaches to Neuroblastoma Therapy Consortium
Sydney Children's Hospital Network
Collaborators
National Cancer Institute (NCI)
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 Years to 30 Years
International registry ID's
NCT02030964
Back to Registry
Study Title N2012-01: NANT 2012-01 Phase 1 study of Difluoromethylornithine (DFMO) and celecoxib with cyclophosphamide/topotecan for patients with relapsed or refractory neuroblastoma
Protocol ID N2012-01
Disease (Sub Disease) Neuroblastoma
Diagnosis Stage Relapse/ refractory
Sponsor New Approaches to Neuroblastoma Therapy Consortium/ Sydney Children's Hospital Network
Collaborators National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT02030964
Trial Status Closed to Recruitment
Trial Open Date 01/12/2013
Study Type Treatment
Phase Phase 1
Age Eligibility 2 Years to 30 Years
International registry ID's NCT02030964

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168